Cabaletta Bio disclosed that its investigational autologous CAR T therapy rese-cel has been manufactured using Cellares’ automated Cell Shuttle platform and dosed into the first two patients. The dosing followed meeting all release criteria, with Cabaletta framing the step as evidence that automated, scalable manufacturing can improve access. Rese-cel is engineered with a fully human CD19 binder and 4-1BB co-stimulatory domain, designed for autoimmune diseases by transiently and deeply depleting CD19-positive cells to “reset” the immune system. Cellares described the milestone as demonstrating GMP manufacturing and supply-chain capabilities with reduced capital requirements and low cost of goods. For the field, the first-in-human dosing built on platform automation adds momentum to efforts to scale autologous cell therapy manufacturing beyond traditional manual, facility-bound processes.